Kodiak Sciences soars on positive Phase 3 wet-AMD trial results
+177.96% to $89.92 from $32.35
What moved KOD
- Kodiak Sciences said its Phase 3 DAYBREAK trial met primary endpoints for both Zenkuda (tarcocimab tedromer) and tabirafusp-ted in patients with wet age-related macular degeneration.
- Zenkuda’s primary endpoint reached a p-value of 0.0007, with the company reporting meaningful vision gains and sustained retinal drying; 54% of patients reached a six-month dosing interval under a strict treat-to-dryness standard.
- Tabirafusp-ted also met its vision primary endpoint and a key anatomical secondary endpoint in the same study.
- Kodiak said it plans to file a Biologics License Application for Zenkuda in the fourth quarter of 2026.
Sources: BioSpace · GuruFocus